Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22

Core Insights - Northstrive Biosciences Inc. has signed a binding term sheet with Modulant Biosciences LLC for a future licensing agreement related to EL-22 in animal health, granting Modulant exclusive global rights to develop and commercialize this intellectual property [1][9] - The licensing agreement will focus on the use of EL-22 as a feed additive, targeting the myostatin pathway to improve body composition in livestock and companion animals [3][9] - Modulant will pay Northstrive a share of revenues generated from sublicensing and commercial activities, with a decreasing royalty rate after reaching a certain revenue threshold [4] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., focusing on developing innovative aesthetic medicines, with EL-22 as its lead asset [6] - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries [7] - Modulant Biosciences LLC specializes in veterinary medicine innovation, led by CEO Tom Campi, who has extensive experience in animal drug development [10]